Editor's Note

Main Article Content

Chusak Okascharoen


As the end of third quarter of 2020, the coronavirus disease 2019 (COVID-19) situation is still worsening in many countries especially overcrowded country like India. Controlling of infection in overcrowded communities are quite challenging. Several clinical trials of vaccine of COVID-19 are ongoing with few candidates have already go to phase 3 trial. It needs to be noted that the first COVID-19 vaccine has been registered in Russia since August.1 The data of safety and efficacy of this COVID-19 vaccine came from only 38 subjects.2 This fact makes scientists around the world expressed some doubt of the data.3 However, the lead author of the report denied all the suspicions.

In term of scientific publication of COVID-19, recent searching in PubMed reveal over 58 000 results and 3489 clinical trials registered in ClinicalTrials.gov. This is a huge number for the period of less than 10 months. We all realize that COVID-19 has change the world in many aspects, and scientific publication is one of those.


Article Details

How to Cite
Okascharoen, C. (2020). Editor’s Note. Ramathibodi Medical Journal, 43(3). Retrieved from https://he02.tci-thaijo.org/index.php/ramajournal/article/view/246252
Editor's Note


Grove T. Russia registers world’s first Covid-19 vaccine despite safety concerns. The Wall Street Journal. August 11, 2020. https://www.wsj.com/articles/russia-registers-worlds-first-covid-19-vaccine-11597141899. Accessed September 30, 2020.

Logunov DY, Dolzhikova IV, Zubkova OV, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet. 2020;396(10255):887-897. doi:10.1016/S0140-6736(20)31866-3.

Abbott A. Researchers highlight ‘questionable’ data in Russian coronavirus vaccine trial results. Nature. September 15, 2020. https://www.nature.com/articles/d41586-020-02619-4. Accessed September 30, 2020.